RESPINOR's DXT is a novel, non-invasive ultrasound-based medical device. Applicable in critical care for accurate and continuous diaphragm monitoring for early detection of diaphragm dysfunction. Secured substantial funding from H2020 and The Research Council of Norway. Successfully completed clinical evidence studies for the first patient segment, mechanical ventilation (MV). RESPNOR is EN ISO 13485:2016 certified and RESPINOR DXT is CE marked. Working towards marketing authorization in the US. DXT offers a huge market potential with >350m patients in US/EU. We aim to become the technology of choice for assessing work of breathing.
DXT, or Diaphragm Excursion Technology, is a groundbreaking non-invasive medical device developed by RESPINOR that utilizes ultrasound for operator-independent, continuous monitoring of the diaphragm, the main breathing muscle, in critically ill patients. This technology aids in the early detection of diaphragm dysfunction and enhances clinical decision-making in critical care settings.
RESPINOR: MedTech innovator specializing in diaphragm monitoring, introducing DXT, a non-invasive ultrasound-based technology to improve critical care and outcomes.